Ultragenyx Pharmaceutical Inc. (RARE) Stock Price Down 2.6%
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price fell 2.6% on Tuesday . The company traded as low as $64.87 and last traded at $65.82, with a volume of 198,133 shares traded. The stock had previously closed at $67.59.
A number of research firms have recently weighed in on RARE. Morgan Stanley reaffirmed a “hold” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. JMP Securities reaffirmed a “buy” rating and issued a $84.00 price objective (up previously from $80.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Jefferies Group reissued a “buy” rating and set a $109.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, June 8th. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday, April 28th. Finally, Credit Suisse Group AG reissued a “buy” rating and set a $101.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 25th. Three analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $99.10.
The firm’s market cap is $2.58 billion. The firm has a 50 day moving average of $57.95 and a 200 day moving average of $61.50.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.02. During the same quarter in the previous year, the firm posted ($0.83) earnings per share. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current year.
In related news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $67.61, for a total value of $1,352,200.00. Following the completion of the transaction, the chief executive officer now owns 493,244 shares in the company, valued at approximately $33,348,226.84. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Sunil Agarwal sold 650 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $66.00, for a total value of $42,900.00. Following the completion of the sale, the insider now owns 7,111 shares in the company, valued at $469,326. The disclosure for this sale can be found here.
A number of large investors have recently bought and sold shares of RARE. Trexquant Investment LP purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at about $1,010,000. Dimensional Fund Advisors LP boosted its stake in Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 5,139 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Ultragenyx Pharmaceutical by 17.0% in the fourth quarter. Jennison Associates LLC now owns 755,388 shares of the biopharmaceutical company’s stock valued at $84,739,000 after buying an additional 109,724 shares during the last quarter.
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.